Annual revenue rose from KRW 198.9 billion in 2022 to KRW 230.4 billion in 2023 (up 15.8% year on year) and KRW 259.6 billion in 2024 (up 12.7%), then edged down to KRW 255.2 billion in 2025 (down 1.7%). The largest year in the 2022–2025 period was 2024.
Operating profit reached a peak of KRW 30.2 billion in 2023 (up 1.2%) and then fell 28.8% to KRW 21.5 billion in 2024 and 39.4% to KRW 13 billion in 2025, a two-year decline.
Net profit attributable to controlling shareholders peaked at KRW 29.8 billion in 2023, then fell 21.5% to KRW 23.4 billion in 2024 and 41.9% to KRW 13.6 billion in 2025. Net profit including non-controlling interests was KRW 13.6 billion in 2025.
The operating margin fell from 15.0% in 2022 to 13.1% in 2023, 8.3% in 2024 and 5.1% in 2025. Cost pressure from the capacity expansion explains much of the decline, as cost of sales rose from 50.34% of revenue in 2022 to 63.88% in 2024 according to a third-party tally.
In its business report, the company attributed the margin decline to higher merchandise cost from the GSK products, higher inventory valuation allowances on export items and higher production costs from equipment investment.
In 2025, labor costs rose from KRW 52.5 billion to KRW 59 billion, and depreciation from KRW 8.5 billion to KRW 9.8 billion.
Quarterly operating profit bottomed at KRW 1.48 billion in the fourth quarter of 2025 on revenue of KRW 65.1 billion, then peaked at KRW 9.38 billion in the first quarter of 2026 on revenue of KRW 71.2 billion.
Operating profit then declined to KRW 7.89 billion in the second quarter and KRW 7.53 billion in the third quarter, while third-quarter revenue reached KRW 71.6 billion.
Cumulative operating profit for the first nine months of 2026 was KRW 24.8 billion, according to a press report on the preliminary disclosure released on October 29, 2026. Operating cash flow was KRW 16.9 billion in 2022, KRW 23.2 billion in 2023, KRW 20.7 billion in 2024 and KRW 9.04 billion in 2025.